Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 15/3/2021
SIETES contiene 93212 citas

 
 
<< anterior 21 a 40 de 201 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Anónimo. Statins and HIV or hepatitis C drugs: drug safety communication - Interaction increases risk of muscle injury. U.S. Food and Drug Administration 2012:2 de marzo. [Ref.ID 92202]
22.Enlace a cita original Cita con resumen
Anónimo. Statin drugs - Drug safety communication: class labeling change. U.S. Food and Drug Administration 2012:1 de marzo. [Ref.ID 92196]
23.
Rowe IA, Mutimer DJ. Protease inhibitors for treatment of genotype 1 hepatitis C virus infection. BMJ 2011;343:1060-3. [Ref.ID 91842]
24. Cita con resumen
Chang C, Gershwin ME. Drug-induced lupus erythematosus. Incidence, management and prevention. Drug Saf 2011;34:357-74. [Ref.ID 90404]
25. Cita con resumen
Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med 2011;364:535-41. [Ref.ID 90172]
26. Cita con resumen
Abecia Inchaurregui LC, Abasolo Osinaga E, Etxeandia Ikobaltzeta I, Burgos Alonso N, López Picado A, Fernández Bilbao M. Evolución de la utilización de hipolipemiantes en la comunidad autónoma del País Vasco (1992-2005). Aten Farmaceutica 2009;11:361-7. [Ref.ID 87455]
27. Cita con resumen
Anónimo. Uncommon knowledge. Drug Ther Bull 2009;47:121. [Ref.ID 87031]
28.Enlace a cita original
Strandell J, Bate A, Hägg S, Edwards IR. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. Br J Clin Pharmacol 2009;68:427-34. [Ref.ID 86710]
29.Enlace a cita original
García del Pozo J, Madurga M, de Abajo FJ. Utilización de hipolipemiantes en España, 1992-2006. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2009:. [Ref.ID 86460]
30.Tiene citas relacionadas
Phillips PS. Balancing randomized trials with anecdote. Ann Intern Med 2009;150:885-6. [Ref.ID 86262]
31.Tiene citas relacionadas
Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009;150:858-68. [Ref.ID 86261]
32.Enlace a cita original
Devold HM, Molden E, Skurtveit S, Furu K. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. Br J Clin Pharmacol 2009;67:234-41. [Ref.ID 85812]
33. Cita con resumen
Hochberg AM, Pearson RK, O'Hara DJ, Reisinger SJ. Drug-versus-drug adverse event rate comparisons: a pilot study based on data from the US FDA Adverse Event Reporting System. Drug Saf 2009;32:137-46. [Ref.ID 85482]
34. Cita con resumen
Tuccori M, Lapi F, Testi A, Coli D, Moretti U, Vannacci A, Motola D, Salvo F, Rivolta AL, Blandizzi C, Mugelli A, Del Tacca M. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous Adverse Drug Reaction Reporting. Drug Saf 2008;31:1115-23. [Ref.ID 84725]
35.Tiene citas relacionadas Cita con resumen
Steinberg D. The statins in preventive cardiology. N Engl J Med 2008;359:1426-7. [Ref.ID 84123]
36. Cita con resumen
Karp I, Behlouli H, Lelorier J, Pilote L. Statins and cancer risk. Am J Med 2008;121:302-9. [Ref.ID 82913]
37. Cita con resumen
Anónimo. Which statin?. Med Lett Drugs Ther 2008;50:29-31. [Ref.ID 82778]
38. Cita con resumen
Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry Jr CP, Habel LA. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361 859 recipients. Pharmacoepidemiol Drug Saf 2008;17:27-36. [Ref.ID 82052]
39. Cita con resumen
Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781-90. [Ref.ID 81617]
40.Tiene citas relacionadas
Seleccionar todas
 
<< anterior 21 a 40 de 201 siguiente >>